· The combination of an alpha-blocker and a 5-alpha reductase inhibitor is an effective regimen for BPH. Withdrawing the alpha-blocker from the combination can be considered if symptoms have been well controlled after 1 year of combination therapy.
The role of 5-alpha reductase inhibitors in prostate pathophysiology: Is there an additional advantage to inhibition of type 1 isoenzyme?. and prostate cancer. Inhibitors of 5-AR such as dutasteride and finasteride may therefore have an important role in the prevention and treatment of BPH.
Role of 5 alpha-reductase inhibitors in the management of. – [Show full abstract] evaluate the role of 5-alpha reductase inhibitors in the prevention and treatment of prostate cancer. The original pcpt data revealed that finasteride reduced the risk of.
Use of 5-alpha-reductase inhibitors as alternatives to luteinizing-hormone releasing hormone (LHRH) analogs or anti-androgens for prostate downsizing before brachytherapy Hee Joon Bae BS a, Omar Mian MD, PhD b, Dhananjay Vaidya PhDc, Theodore L. DeWeese MD a, Daniel Y. Song MD a,
· Men treated with 5-alpha reductase inhibitors were diagnosed with prostate cancer 2 years later than men not using these drugs.
Purpose: We determined whether intravesical recurrence is affected by inhibition of androgen signaling among men with nonmuscle invasive bladder cancer.Materials and Methods: We examined the intravesical recurrence rate among men treated with or without androgen suppression therapy by androgen deprivation therapy for prostate cancer or 5-reductase inhibitor dutasteride for benign prostatic.
– Consider at age 45 years in men at high risk for prostate cancer (African-Americans and men with a close relative with prostate cancer). – Consider at age 40 years in men with multiple close relatives with prostate cancer. For this age group, if the PSA result is less than 2.5, retest in 2 years; if >2.5 then retest in one year.
· Prostate cancer also appears to be more aggressive in african american men, transforming into advanced metastatic disease at a 4:1 ratio compared with white patients.
· Benign prostatic hyperplasia (BPH), also known as benign prostatic hypertrophy, is a histologic diagnosis characterized by proliferation of the cellular elements of the prostate. Cellular accumulation and gland enlargement may result from epithelial and stromal proliferation, impaired preprogrammed cell death (apoptosis), or both.
This trial previously indicated that finasteride, a 5-alpha-reductase inhibitor commonly used for benign prostatic hyperplasia and male pattern baldness, is an effective chemopreventive agent for.